Cell-free DNA-based liquid biopsies showed promise for monitoring response to pancreatic cancer therapies and making ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...

Novocure (Nasdaq:NVCR) today announced positive results from the Phase 3 PANOVA-3 trial of its tumor-treating fields (TTFields) therapy.